BCTX · BriaCell Therapeutics Corp. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“However, the Company's ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to continue to obtain the necessary financing to meet its obligations arising from normal business operations when they come due. The uncertainty of the Company's ability to raise such financial capital casts substantial doubt on the Company's ability to continue as a going concern.”View the 10-Q filed Jun 9, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2024-05-14 | Lustig Marc |
Director, 10% Owner |
Buy↑
Filing footnotes — Common Shares (Indirect)
The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer. |
Common Shares
(I)
|
902,935 |
| 2024-05-14 | Lustig Marc |
Director, 10% Owner |
Buy↑
Filing footnotes — Common Stock Warrants (Indirect)
The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer. |
Common Stock Warrants
(I)
|
902,935 |
| 2022-12-28 | Bondarenko Jamieson |
Director, Chairman |
Buy↑
|
Common Shares
|
28,000 |
| 2022-12-23 | Williams William V. |
Director, President, CEO |
Buy↑
Filing footnotes — Warrant (Direct)
The price reported in Column 8 is a weighted average price. These Warrants were purchased in multiple transactions at prices ranging from $1.97 to $2.00 per Warrant, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Warrants purchased at each separate price within the ranges set forth herein. |
Warrant
|
2,530 |
| 2022-12-20 | Bondarenko Jamieson |
Director, Chairman |
Buy↑
|
Common Shares
|
22,000 |